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In this issue of Critical Care, Poeze and coworkers [1]
report the results of an international survey of physicians’
attitudes about sepsis. There are several important
messages for clinicians that emerge when reviewing the
results of this survey. First, most physicians believed there
was no single consensus definition of sepsis, despite the
original consensus definitions published in 1992 [2].
Second, the large majority of intensivists believed that
better monitoring is needed to diagnosis sepsis earlier.
Third, the large majority of respondents believed that
patients are treated too late to reverse the onset of sepsis.
Finally, patients and their families have a poor
understanding of the condition, which makes
communication with care givers difficult.
Taken together, these findings identify the challenges most
clinicians face when dealing with sepsis in the intensive care
unit, namely how best to identify these patients, when to
initiate treatment, how to monitor the progress (both
resolution and deterioration) of the disease, and how to
communicate with patients and families about the nature of
one of the most common diseases in critically ill patients.
In the past the need for clinicians to identify and stage
critically ill patients with sepsis at the bedside was less
important than it is today. Until recently few interventions
were available to clinicians that may improve survival in
patients critically ill with severe sepsis or septic shock. For
many years, the only interventions of proven value in the
treatment of patients with sepsis were early institution of
appropriate antibiotics, adequate resuscitation, and, finally,
good source control [3,4]. These interventions were and
continue to be fundamental components of management for
critically ill patients with sepsis. However, these interventions,
although of obvious importance, were applicable to all
patients with infection. They were not specific to patients
with sepsis, severe sepsis, or septic shock. Therefore, the
need to identify and stage patients with sepsis was of little
clinical importance, and there was no impetus for the
bedside clinician to value a staging system for sepsis. This
almost certainly has fostered confusion, expressed by the
survey respondents, regarding clear definitions of sepsis.
It is important to note that each of the issues raised by
respondents in the survey has been addressed in the literature
over the past several years. These have led to significant
changes in the way in which diagnosis and treatment of
sepsis in critically ill patients should be approached.
In response to this survey, conducted in 2001, an
international sepsis definitions conference, sponsored by
several international critical care societies, was convened in
2001 and tasked with revisiting the sepsis definitions
originally published in 1992. The findings of the conference
were published in 2002 and reaffirmed the original three
stages of the host response to infection [5]: sepsis, severe
sepsis, and septic shock. For the practicing clinician, there are
now clearly defined consensus definitions of sepsis.
Unfortunately, we still lack precise markers that permit early
identification of these critically ill patients. However, a staging
system, which remains hypothesis generating, was identified
by the international definitions conference. This system,
named PIRO (predisposition, infection, response, and organ
dysfunction), is a model designed to stage as well as monitor
the host response to infection on the basis of factors believed
to be pertinent to outcomes. Whether the PIRO system will
evolve into a useful tool for bedside clinicians will depend on
the results of future investigations and epidemiologic studies.
Recently published studies have demonstrated decreased
mortality and morbidity as a result of interventions and
therapeutics applied to patients with sepsis [6–9]. These
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new data, resulting from rigorously performed, randomized
controlled trials, combined with previous data for beneficial
interventions not specific to sepsis management [9–13], lend
significant weight to the belief that critical care clinicians can
now significantly reduce mortality in patients with severe
sepsis and septic shock. These studies have changed the
way in which management of sepsis is now viewed by
clinicians. Results from these studies are so robust that they
have formed the basis for consensus guidelines that were
recently published [14,15] and that, taken together, are the
foundation for a new, global standard of care in the
management of sepsis.
The publication of Surviving Sepsis Campaign guidelines
for management of severe sepsis and septic shock earlier
this year [14,15] was the culmination of phase II of the
Surviving Sepsis Campaign. Initiated by the combined
efforts of the International Sepsis Forum, the European
Society of Intensive Care Medicine, and the Society of
Critical Care Medicine in 2002, the Campaign is an
international effort to facilitate improvements in sepsis
treatment and management through the implementation of
guidelines to create a global standard of care for sepsis,
thereby reducing mortality from sepsis by 25% over
5 years. An unprecedented 11 organizations sponsored the
evidence-based and expert opinion guidelines. Another of
the stated goals of the Campaign, and one that directly
addresses an issue identified by the survey, is to raise
public awareness of sepsis as a common and deadly
disease in critically ill patients.
Although there remains a lack of clear markers that might
permit precise, early identification and staging of patients
with sepsis, clinicians do have important new tools that may
assist in the management of these critically ill patients and
lead to improved care and survival. The use of consensus
definitions for severe sepsis and septic shock will allow
identification of those patients who may benefit from the
application of the guidelines for management.
Unfortunately, clinicians change very slowly. Historically,
transfer of research from the bench to the bedside is a
long, tortuous process – one that is not driven by anything
very clear and that seems to be based more on fad and
coincidence than on a keen, evidence-based evaluation of
the literature. Changing clinicians’ behaviors in response to
published data has long been a glaring failure in medicine.
The Surviving Sepsis Campaign represents an important
step for international critical care societies. Recognizing the
long history of delay in incorporating research into bedside
care, these critical care societies have committed to
working together to facilitate bench-to-bedside transfer of
recent research. In this way, the responses of the
participants in the survey published in this issue of Critical
Care may serve to improve the care for patients with severe
sepsis and septic shock.
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